Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia - 101307

Spotlight
Video

Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia

AudioMedica has 12 videos Subscribe Here

Loading........
Description: NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weill Cornell Medical College in New York announced findings at the American Society of Hematology Annual Meeting of a phase III, double blind, placebo-controlled study randomising patients to have idelalisib or placebo added to their rituximab treatment. He discussed the clinical implications with AudioMedica.com of the extension of both progression-free and overall survival among patients receiving the new agent in comparison with placebo. Jennifer Brown MD PhD, Director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute in Boston added her comments and explained why she considered idelalisib is a good candidate for early approval.

CONTACT:
Dr. Richard Furman MD
SOURCE:
Abstract LBA 6
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

LINK:
https://ash.confex.com/ash/...
Shared By : AudioMedica
Posted on : 03/12/14
Added : 4 years ago
Category : other



More From AudioMedica

Nothing found.